Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Depreciation & Amortization (CF) (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $5000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 44.44% to $5000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $21000.0, a 54.35% decrease, with the full-year FY2025 number at $21000.0, down 54.35% from a year prior.
  • Depreciation & Amortization (CF) was $5000.0 for Q4 2025 at Spruce Biosciences, up from $3000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $24000.0 in Q4 2022 to a low of $3000.0 in Q3 2025.
  • A 4-year average of $13187.5 and a median of $13500.0 in 2024 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 200.0% in 2023, then tumbled 70.0% in 2025.
  • Spruce Biosciences' Depreciation & Amortization (CF) stood at $24000.0 in 2022, then crashed by 33.33% to $16000.0 in 2023, then plummeted by 43.75% to $9000.0 in 2024, then tumbled by 44.44% to $5000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Depreciation & Amortization (CF) are $5000.0 (Q4 2025), $3000.0 (Q3 2025), and $7000.0 (Q2 2025).